Business Context and Reporting Period
Immunome, Inc. (IMNM) is a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class therapies, including antibody-drug conjugates (ADCs) and radioligand therapies. This Form 10-Q covers the quarterly period ended September 30, 2025. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, though it expects to lose emerging growth status effective December 31, 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Collaboration Revenue | $0 | $2.9 million | $6.9 million | $6.3 million |
| Total Operating Expenses | $60.1 million | $53.4 million | $158.2 million | $229.1 million |
| Net Loss | $(57.5) million | $(47.1) million | $(142.5) million | $(212.7) million |
| Net Loss Per Share (Basic/Diluted) | $(0.65) | $(0.78) | $(1.68) | $(3.72) |
| Cash and Cash Equivalents (Sept 30, 2025) | $272.6 million | |||
| Accumulated Deficit (Sept 30, 2025) | $(658.3) million |
Liquidity: As of September 30, 2025, the company held $272.6 million in cash and cash equivalents. Management expects these funds to be sufficient to finance operations for at least 12 months from the filing date. The company has no debt obligations listed on the balance sheet.
Material Changes vs. Prior Period
- Revenue Cessation: Collaboration revenue dropped to zero in Q3 2025 compared to $2.9 million in Q3 2024. This is due to the termination of the Collaboration Agreement with AbbVie in July 2025, under which all remaining revenue was recognized by June 30, 2025.
- Expense Reduction (9 Months): Total operating expenses decreased by $70.9 million year-over-year for the nine-month period. This significant reduction is primarily driven by the absence of $125.0 million in In-Process Research and Development (IPR&D) expenses incurred in 2024 related to the acquisitions of assets from Zentalis and Ayala Pharmaceuticals.
- R&D Spend Increase (Q3): Despite the 9-month reduction, Q3 2025 R&D expenses increased by $12.0 million compared to Q3 2024. This increase was driven by higher costs for the Phase 3 trial of varegacestat and increased personnel costs.
- Capital Raising: In January 2025, the company completed a public offering raising net proceeds of $161.7 million. Additionally, $44.9 million in net proceeds were generated via an "at-the-market" (ATM) offering during the nine months ended September 30, 2025.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- Varegacestat: The lead asset is in a Phase 3 registrational trial for desmoid tumors. Topline data is expected in the second half of 2025.
- IM-1021: A Phase 1 trial for this ROR1 ADC is ongoing, with initial data expected in 2026.
- IM-3050: Received IND clearance in April 2025; Phase 1 trial initiation is planned for early 2026.
Management Commentary: Management anticipates that expenses will increase substantially as the company advances clinical development and prepares for potential New Drug Application (NDA) submissions. The company expects to continue incurring losses for the foreseeable future.
Risks and Contingencies:
- Funding Requirements: The company will need additional financing to support operations beyond the next 12 months. Future capital may be raised through equity offerings, debt, or collaborations, which could result in dilution.
- Regulatory and Clinical Risks: Success depends on the outcome of clinical trials, particularly the Phase 3 trial for varegacestat. Failure to achieve positive results or regulatory approval would materially harm the business.
- Third-Party Reliance: The company relies on third-party vendors for manufacturing and clinical trial conduct, creating supply chain and execution risks.
- Intellectual Property: Risks include the inability to protect proprietary technology or infringement claims by third parties.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $272.6 million cash balance against the projected burn rate, given the expectation of increased R&D spending for Phase 3 trials.
- Revenue Sustainability: Confirm the timeline for any new collaboration agreements or product revenue, as the AbbVie revenue stream has ceased.
- Phase 3 Trial Status: Monitor the enrollment and data readout timeline for the varegacestat Phase 3 trial, which is the primary near-term catalyst.
- Dilution Impact: Review the remaining capacity under the ATM agreement ($134.1 million) and potential future equity issuances required to fund operations.
- IPR&D Accounting: Note that the significant expense reduction in 2025 is due to the lack of large asset acquisitions compared to 2024, not necessarily a reduction in operational burn.